The world of medical science has witnessed a groundbreaking achievement with the successful administration of the first gene therapy for WOREE syndrome to an eight-month-old infant. This remarkable feat, achieved at the Schneider Children's Medical Center of Israel, marks a significant milestone in the field of precision genetic therapies for rare neurological disorders. The infant, who suffered from severe genetic epilepsy, received a gene replacement therapy designed to restore the function of the WWOX gene directly in the brain, offering a glimmer of hope for families affected by this devastating condition.
WOREE syndrome, a rare inherited disorder, is characterized by early-onset, drug-resistant epilepsy, profound developmental impairment, and a high risk of premature death. The infant's genetic testing revealed a rare defect in the WWOX gene, which is known to cause severe neurodevelopmental disorders. This discovery led to a decade-long research effort led by Prof. Rami Aqeilan, who, along with a team of scientists, clinicians, and biotechnology leaders from Israel and the United States, developed a gene replacement strategy using an adeno-associated viral vector (AAV9) to deliver a healthy copy of the WWOX gene to neurons.
The research team's findings, published in a scientific journal, demonstrated that the loss of the WWOX gene in the brain causes severe neurological abnormalities, including epilepsy, developmental delay, defective myelination, and premature death, closely mirroring the symptoms observed in children with WOREE syndrome. This discovery not only sheds light on the critical role of WWOX in normal brain development and neurological function but also provides a potential therapeutic strategy for children affected by this severe form of genetic epilepsy.
The infant's treatment, administered through a compassionate-use program, has shown promising results. One month after the therapy, the child remained clinically stable and was discharged from the hospital, with no recurrence of severe seizures. However, long-term clinical follow-up is essential to evaluate the safety and efficacy of the treatment. This achievement highlights the power of combining scientific discovery, clinical excellence, and international collaboration, offering hope for families affected by WWOX-related disorders worldwide.
The breakthrough builds upon Prof. Aqeilan's internationally recognized research, which established WWOX as a critical regulator of nervous system development and function. The work has received international support, including a European Research Council Proof-of-Concept grant, aimed at advancing WWOX gene therapy toward clinical application. While the infant will continue to be closely monitored, this treatment represents an important step in the development of personalized therapies for rare genetic epilepsies, offering a beacon of hope for the future of medical science.
